Resources

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy); Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL

New data shows investing in life sciences produces great returns, London Life Sciences Week and #bioProcessUK are nearly here.

The first Budget of the new government will be presented this Wednesday. It’s an important moment, not just for life sciences but for the broader UK economy. Read this blog for an update on the Life Sciences Council, and the launch of our latest Influencing and shaping our sector report.

Landmark studies represent the largest investigational trials to be conducted to date for cannabinoids as a treatment for refractory epilepsy.

Steve Bates OBE, CEO of the BIA, responded to the announcement of a new Regulatory Innovation Office.

In this blog, the BIA's Senior Policy and Public Affairs Manager, Dr Emma Lawrence, discusses the life science implications of Lord Darzi's review.

Accession Therapeutics Limited, which is developing novel, first-in-class immunotherapies targeted at tumour sites and administered systemically to provide a step-change in cancer treatment has filed a Clinical Trial Application (CTA) with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This is the first clinical trial showcasing the company’s TROCEPT-01 lead program and will enrol patients with a variety of solid tumour carcinomas including non-small cell lung, bladder, pancreatic, head and neck, cholangiocarcinoma and endometrial cancers.

Vertex Pharmaceuticals announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassaemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel), from today.

Connect with Fellow Leaders Shaping Cell and Gene Therapy Development

The UK general election has been called for Thursday, 4 July. In practical terms, this means the end of the legislative pathway for many proposals as Parliament shuts down. It also means the policy-making function of the civil service machine slows to a crawl and with it the cancellation of planned formal meetings of government and industry, like the Life Science Council in June. Keep reading for updates on our general election webinars and UK events at BIO 2024.

The UK General Election has been called for Thursday, 4 July. In practical terms, this means the end of the legislative pathway for many proposals as Parliament shuts down. Keep reading for updates on our general election webinars and UK events at BIO 2024.

It was wonderful to celebrate with RNID, our charity partner of the year, the news that pioneering gene therapy has restored a UK girl's hearing. Read on for updates on MHRA AI-Airlock, AMR action plan and more...

Much of the UK will go to the polls this Thursday in the biggest test of public opinion ahead of the UK general election. Ten key metro mayoral contests take place including in Tees Valley, Manchester, the West and East Midlands and London. The results will be announced over the weekend and give a new mandate to key figures in regions of the UK whilst also helping define if we will have a summer or autumn general election.

The UK's engineering biology scene was out in force at a Number 10 Downing Street reception last week. It was great to celebrate the developments in our community network together with ministers and investors.